Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults.

Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan

Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan.

Afiliación

Chen G; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Li N; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Dai X; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Tu S; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
Shen Z; Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Wu K; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Jin T; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Wu J; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Peng C; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Sheng G; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China. guoping.sheng@shulan.com.
Zhu M; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China. mengfei.zhu@shulan.com.
Tang L; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China. lingling.tang@shulan.com.
Li L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310

Infect Dis Ther ; 12(2): 663-675, 2023 Feb.

Article en En | MEDLINE | ID: mdl-36697937

Palabras clave

C5a; Clinical trial; Complement system; Phase 1; Severe COVID-19

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Infect Dis Ther Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google